Reviewed by Sarah Alter, Ph.D. — Scientific Affairs, OrganaBio. 15 years of immunology research spanning autoimmunity, cancer, and infectious disease. University of Miami Miller School of Medicine. Registered Patent Agent.
The Source Decision No One Teaches Explicitly
Peripheral blood, bone marrow, and cord blood all supply immune cells for cell therapy programs. Each produces a fundamentally different starting cell population with different biology, different clinical procurement logistics, and different scalability profiles. The wrong choice early doesn’t just affect discovery data — it determines manufacturing feasibility, regulatory comparability requirements, and what your Phase I trial can actually accomplish.
Most programs default to peripheral blood PBMCs because leukopaks are commercially available, well-characterized, and the literature is dense with protocols built on them. That default is right for a large fraction of programs. For others, it produces clean early data that deteriorates when the clinical reality asserts itself.
This is a decision framework. Not a literature review. The goal is to give your program the criteria to make the right call before the wrong choice becomes expensive to reverse.
Peripheral Blood: What It Actually Provides
Peripheral blood via apheresis — collected as a leukopak and processed to PBMCs — is the dominant starting material source for a clear set of reasons.
Cell composition: PBMCs from peripheral blood are predominantly T cells (60-80%), B cells (5-15%), NK cells (5-15%), and monocytes (10-20%), with a small dendritic cell fraction. The T cell compartment is dominated by mature, antigen-experienced cells — central and effector memory T cells with defined TCR specificities, not naive progenitors. This is the starting point for CAR-T manufacturing, Treg isolation, NK cell expansion, and most T cell receptor therapy programs.
Availability and scalability: Leukopak apheresis from healthy volunteer donors is the most commercially scalable cell collection method available. A single leukopak yields 5-20 billion PBMCs. OrganaBio’s coast-to-coast apheresis network — Miami and San Diego — supports same-day processing with controlled logistics that preserve functional quality from collection through isolation. For allogeneic programs that need consistent supply across multiple manufacturing runs, peripheral blood donor pools are the only source with the depth to support it.
Clinical familiarity: More Phase I trials have used peripheral blood-derived starting material than any other source. Regulatory agencies have established precedent for characterizing, qualifying, and releasing PBMC-derived therapeutic products. The documentation requirements are well-understood. This reduces regulatory uncertainty relative to less common sources.
Where peripheral blood falls short: The mature T cell compartment is the starting point, which means you’re working with cells that have already committed to lineages, carry exhaustion markers from prior antigen exposure, and have limited long-term persistence potential compared to less differentiated progenitors. For programs that need stem-like T cell progenitors, progenitor NK cells, or hematopoietic stem cells for T cell derivation, peripheral blood provides the wrong developmental stage.
For autoimmune programs, peripheral blood from disease-state donors captures the systemic immune signature of the disease — which is what you need. Read the decision framework for disease-state vs. healthy donor PBMCs before specifying peripheral blood source for any inflammatory indication.
Bone Marrow: The Progenitor Advantage and the Procurement Cost
Bone marrow provides hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) that can be directed toward T cell, NK cell, or dendritic cell lineages under appropriate culture conditions. It also contains mesenchymal stromal cells (MSCs) that are not present in peripheral blood and have distinct immunomodulatory applications.
Where bone marrow is the right source:
HSC-derived T cell programs — including programs that derive T cells from HSCs to generate a T cell product with defined TCR or CAR specificity — require bone marrow or mobilized peripheral blood HSCs. Starting from HSCs allows control over T cell differentiation, selection for specific progenitor pools, and potentially longer-lived T cell products with stem-like memory characteristics. For programs specifically developing T cells with defined TCR specificity via thymic selection analogs or artificial thymic organoids, bone marrow-derived HSCs are the required starting point.
MSC programs for tolerogenic or stromal applications require bone marrow specifically — peripheral blood does not provide MSCs at recoverable frequencies without mobilization protocols.
Allogeneic HSC transplant-adjacent programs — where the therapeutic construct needs to engraft long-term and reconstitute immune function — require bone marrow-derived progenitors. Mature T cells from peripheral blood will not engraft as progenitors.
Where bone marrow is the wrong choice: Procurement is invasive, yield per donor is lower than apheresis, and the logistics of transporting viable marrow within functional windows limits geographic flexibility. For programs that need large-scale, repeatable manufacturing from a stable donor pool, bone marrow cannot match peripheral blood leukopak supply scalability. Regulatory familiarity with bone marrow-derived starting material for specific therapeutic applications exists, but the literature base is thinner than for peripheral blood.
Cord Blood: The Immune Naivety Trade-Off
Cord blood collected at birth provides hematopoietic stem and progenitor cells with higher CD34+ frequency than adult peripheral blood, and a T cell compartment that is predominantly naive — no prior antigen exposure, no existing exhaustion, no established memory against common pathogens or self-antigens. This immune naivety is simultaneously cord blood’s major advantage and its major limitation.
Where cord blood has genuine advantages:
NK cell therapy programs have shown particular interest in cord blood-derived NK cells. Cord blood NK cells are more proliferative than peripheral blood NK cells from adult donors, lack the inhibitory KIR repertoire that matures with age, and have a functional profile that some programs find advantageous for antitumor activity. Several clinical-stage allogeneic NK cell therapy programs use cord blood as their starting material for this reason.
T cell programs that specifically benefit from naive T cells — particularly programs involving TCR or CAR introduction into cells that will then undergo primary T cell priming — may find cord blood’s naive T cell starting point advantageous for generating de novo antigen-specific responses without interference from pre-existing memory.
Where cord blood falls short: Immune naivety means cord blood-derived T cells lack the memory phenotype that contributes to persistence in adoptive transfer settings. They require differentiation protocols to generate functional effector populations, adding manufacturing complexity. Supply is fundamentally constrained by birth event logistics — you cannot recall a cord blood donor for additional collections the way you can recall an adult apheresis donor. For programs that need large-scale, consistent, repeat-collection manufacturing, cord blood’s supply ceiling is a structural limitation.
For autoimmune programs, cord blood’s naive T cell and NK cell compartments do not reflect the chronically activated, exhausted, or disease-conditioned immune profiles relevant to modeling or treating established autoimmune disease. Cord blood is irrelevant as a disease-state model for any chronic inflammatory condition.
The Mobilized Peripheral Blood HSC: The Middle Path
G-CSF or plerixafor mobilization of HSCs into peripheral blood, followed by apheresis collection and CD34+ selection, provides hematopoietic progenitors via peripheral blood collection rather than bone marrow harvest. This approach combines some of the progenitor biology available from bone marrow with the logistics advantages of apheresis.
Mobilized HSC collection is the standard for autologous transplant programs and allogeneic transplant from matched donors. For cell therapy manufacturing that needs HSC-level progenitors without bone marrow aspiration logistics, mobilized peripheral blood is the practical middle ground.
The limitations: mobilization requires clinical protocols and donor eligibility criteria that restrict the donor pool more than simple leukopak apheresis. The CD34+ fraction is a small fraction of the mobilized collection, requiring selection steps. For programs that need large-scale progenitor manufacturing from a broad donor pool, mobilized HSC apheresis is more complex to operationalize than leukopak collection.
Decision Matrix: Which Source for Which Program
| Program Type | Recommended Source | Key Reason |
|---|---|---|
| CAR-T (autologous or allogeneic) | Peripheral blood leukopak | T cell yield, scalability, regulatory precedent |
| NK cell therapy (off-the-shelf) | Peripheral blood or cord blood | PB for scalability; CB for naive NK phenotype advantage |
| Treg therapy (autoimmune) | Peripheral blood (disease-state) | Disease-conditioned Tregs required for potency modeling |
| HSC-derived T cell programs | Bone marrow or mobilized PB | Progenitor biology unavailable in mature PB T cells |
| MSC therapy (tolerogenic) | Bone marrow | MSCs not recoverable from peripheral blood |
| Allogeneic autoimmune (alloreactivity modeling) | Peripheral blood (HLA-typed, disease-state) | Disease-specific HLA distributions required for MLR |
| Cord-blood NK cell programs | Cord blood | Naive NK phenotype, high proliferative capacity |
What This Means for Supplier Selection
The source decision determines which suppliers can actually support your program. A supplier with strong peripheral blood leukopak infrastructure and poor bone marrow access is the wrong partner for an HSC program, regardless of other qualifications. A supplier without disease-state donors is the wrong partner for autoimmune Treg programs regardless of healthy donor volume.
OrganaBio’s primary strength is peripheral blood starting material — fresh and cryopreserved leukopaks, isolated PBMC and specific cell subsets, and disease-state donor pools across 24 indications with HLA typing, clinical annotation, and recallable donor capabilities. For programs that need disease-state peripheral blood material or HLA-characterized material for allogeneic programs, OrganaBio’s starting material depth is a direct fit.
Contact our scientific team to discuss starting material source selection for your program. The right conversation at the source selection stage is substantially less expensive than the wrong conversation after Phase I data.
